Health

STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 12/11/2026, 11:36:24 UTC.

Briefings

A STAT newsletter report from August 2025 suggests Alnylam's rapid growth driven by Amvuttra could surpass Vertex's market cap. The article notes Alnylam's $60 billion valuation and $100 billion target, but explicitly states it is not a direct competitor to Vertex.

Key points

• Alnylam's Amvuttra sales are driving its $60 billion market value toward potentially matching Vertex's $100 billion market cap.
• The report explicitly states Alnylam and Vertex are not direct competitors, despite the valuation comparison.

Context

STAT+ newsletter Adam's Biotech Scorecard analyzes biotech valuations, specifically comparing Alnylam's Amvuttra growth to Vertex's market cap.

Limitations

Evidence is limited to a single newsletter snippet from August 2025; no additional data on Amvuttra sales, Vertex's specific market cap trajectory, or future growth forecasts is provided.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 12/11/2026, 13:11:02 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeichc6i5u2yocr7yrkgpcy7niefccil6joeh3ng5uvznxknnc2zlka